Endocyte Reports Second Quarter Financial Results and Provides Clinical Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St futures ease as Big Tech earnings rekindle AI spending worries, oil jumps
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Dollar hits fresh 40-year high versus yen, edges down against euro
Chardan Capital Affirms Endocyte (ECYT) at Buy Following Q2 Results, Operational Update
July 30, 2014 2:49 PM EDTChardan Capital affirms Endocyte (Nasdaq: ECYT) at Buy with a price target of $15 following Q2 results and updated information of EC1456.
Analyst Ling Wang commented, ECYT reported 2Q14 EPS of $0.54, vs. consensus... More
